264 related articles for article (PubMed ID: 9212906)
1. In vivo metabolic profile of a phosphorothioate oligodeoxyribonucleotide.
Temsamani J; Roskey A; Chaix C; Agrawal S
Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):159-65. PubMed ID: 9212906
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and metabolism of an oligodeoxynucleotide phosphorothioate (GEM91) in cynomolgus monkeys following intravenous infusion.
Grindel JM; Musick TJ; Jiang Z; Roskey A; Agrawal S
Antisense Nucleic Acid Drug Dev; 1998 Feb; 8(1):43-52. PubMed ID: 9512095
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of antisense oligonucleotides.
Agrawal S; Temsamani J; Galbraith W; Tang J
Clin Pharmacokinet; 1995 Jan; 28(1):7-16. PubMed ID: 7712663
[TBL] [Abstract][Full Text] [Related]
4. Antisense oligodeoxynucleotide phosphorothioate complementary to Gag mRNA blocks replication of human immunodeficiency virus type 1 in human peripheral blood cells.
Lisziewicz J; Sun D; Weichold FF; Thierry AR; Lusso P; Tang J; Gallo RC; Agrawal S
Proc Natl Acad Sci U S A; 1994 Aug; 91(17):7942-6. PubMed ID: 8058738
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice.
Saijo Y; Perlaky L; Wang H; Busch H
Oncol Res; 1994; 6(6):243-9. PubMed ID: 7865900
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion.
Iversen PL; Mata J; Tracewell WG; Zon G
Antisense Res Dev; 1994; 4(1):43-52. PubMed ID: 8061515
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression.
Geary RS; Leeds JM; Fitchett J; Burckin T; Truong L; Spainhour C; Creek M; Levin AA
Drug Metab Dispos; 1997 Nov; 25(11):1272-81. PubMed ID: 9351904
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects.
Zhang R; Yan J; Shahinian HK; Amin G; Lu Z; Liu T; Saag MS; Jiang Z; Temsamani J; Martin RR
Clin Pharmacol Ther; 1995 Jul; 58(1):44-53. PubMed ID: 7628182
[TBL] [Abstract][Full Text] [Related]
9. Absolute bioavailability of 2'-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats.
Geary RS; Khatsenko O; Bunker K; Crooke R; Moore M; Burckin T; Truong L; Sasmor H; Levin AA
J Pharmacol Exp Ther; 2001 Mar; 296(3):898-904. PubMed ID: 11181922
[TBL] [Abstract][Full Text] [Related]
10. The multiple inhibitory mechanisms of GEM 91, a gag antisense phosphorothioate oligonucleotide, for human immunodeficiency virus type 1.
Yamaguchi K; Papp B; Zhang D; Ali AN; Agrawal S; Byrn RA
AIDS Res Hum Retroviruses; 1997 May; 13(7):545-54. PubMed ID: 9135872
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice.
Raynaud FI; Orr RM; Goddard PM; Lacey HA; Lancashire H; Judson IR; Beck T; Bryan B; Cotter FE
J Pharmacol Exp Ther; 1997 Apr; 281(1):420-7. PubMed ID: 9103525
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic properties of 2'-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats.
Geary RS; Watanabe TA; Truong L; Freier S; Lesnik EA; Sioufi NB; Sasmor H; Manoharan M; Levin AA
J Pharmacol Exp Ther; 2001 Mar; 296(3):890-7. PubMed ID: 11181921
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of oligonucleotides.
Agrawal S; Zhang R
Ciba Found Symp; 1997; 209():60-75; discussion 75-8. PubMed ID: 9383569
[TBL] [Abstract][Full Text] [Related]
14. Clinical trial results of GEM91 show activity against advance HIV.
AIDS Patient Care STDS; 1997 Aug; 11(4):290-1. PubMed ID: 11361850
[No Abstract] [Full Text] [Related]
15. Pharmacokinetic properties of several novel oligonucleotide analogs in mice.
Crooke ST; Graham MJ; Zuckerman JE; Brooks D; Conklin BS; Cummins LL; Greig MJ; Guinosso CJ; Kornbrust D; Manoharan M; Sasmor HM; Schleich T; Tivel KL; Griffey RH
J Pharmacol Exp Ther; 1996 May; 277(2):923-37. PubMed ID: 8627575
[TBL] [Abstract][Full Text] [Related]
16. Distribution and stability of antisense phosphorothioate oligonucleotides in rodent brain following direct intraparenchymal controlled-rate infusion.
Broaddus WC; Prabhu SS; Gillies GT; Neal J; Conrad WS; Chen ZJ; Fillmore H; Young HF
J Neurosurg; 1998 Apr; 88(4):734-42. PubMed ID: 9525721
[TBL] [Abstract][Full Text] [Related]
17. Hairpin antisense oligonucleotides containing 2'-methoxynucleosides with base-pairing in the stem region at the 3'-end: penetration, localization, and Anti-HIV activity.
Kuwasaki T; Hosono K; Takai K; Ushijima K; Nakashima H; Saito T; Yamamoto N; Takaku H
Biochem Biophys Res Commun; 1996 Nov; 228(2):623-31. PubMed ID: 8920960
[TBL] [Abstract][Full Text] [Related]
18. In vivo stability, disposition and metabolism of a "hybrid" oligonucleotide phosphorothioate in rats.
Zhang R; Lu Z; Zhao H; Zhang X; Diasio RB; Habus I; Jiang Z; Iyer RP; Yu D; Agrawal S
Biochem Pharmacol; 1995 Aug; 50(4):545-56. PubMed ID: 7646561
[TBL] [Abstract][Full Text] [Related]
19. A nonradioisotope approach to study the in vivo metabolism of phosphorothioate oligonucleotides.
Cohen AS; Bourque AJ; Wang BH; Smisek DL; Belenky A
Antisense Nucleic Acid Drug Dev; 1997 Feb; 7(1):13-22. PubMed ID: 9055034
[TBL] [Abstract][Full Text] [Related]
20. Tissue distribution and physiologically based pharmacokinetics of antisense phosphorothioate oligonucleotide ISIS 1082 in rat.
Peng B; Andrews J; Nestorov I; Brennan B; Nicklin P; Rowland M
Antisense Nucleic Acid Drug Dev; 2001 Feb; 11(1):15-27. PubMed ID: 11258618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]